1Q23 Business Results
Pipeline
Product Name
Reference Drug
Manufacturer
Indication
Global Market Size
($bn)
US
CT-P43
StelaraⓇ
(Ustekinumab)
Johnson
Autoimmune Disease
17.7
& Johnson
EU
Completed Global Phase 3 Clinical Trials
(Sep 2022)
CT-P39
XolairⓇ
(Omalizumab)
Completed Global Phase 3
Asthma,
Genentech
3.8
Clinical Trials
Chronic Idiopathic Urticaria
Application Submitted
(Apr 2023)
(Apr 2023)
CT-P42
EyleaⓇ
(Aflibercept)
Bayer
Aged Macular Degeneration
9.6
& Regeneron
CT-P41
ProliaⓇ
(Denosumab)
Amgen
Osteoporosis
Completed Global Phase 3 Clinical Trials
(Apr 2023)
6.2
In Global Phase 3 Clinical Trials
CT-P47
Actemra®
(Tocilizumab)
Roche
Autoimmune Disease
2.8
In Global Phase 3 Clinical Trials
CT-P53
OcrevusⓇ
(Ocrelizumab)
Roche
Multiple Sclerosis
6.7
Note: 1) Global market size is as of 2022, 2) Launching plan could be subjective to the approval
Source: IQVIA, Regeneron (Eylea)
Application Submitted
for Global Phase 3 Clinical Trials
Investor Relations 2023 16
1Q23 Business Results Key Products
Plan & Vision
AppendixView entire presentation